Effects of some biological factors on Coronavirus
Main Article Content
Keywords
Patient, Covid, Infection, Virus
Abstract
This research was been adopted to study the relationship between Covid and some necessary biological factors in human body and how these factors affected, This studying included three stages (Sever – Moderate – Mild) it was studied 20 patient for every stage and monitor the biological factors during infection and after infection.
References
1. Cai Q, Chen F and Wang T., 2020, Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care.;43(7):1392-1398.
2. Centers for Disease Control and Prevention. COVID-19 (coronavirus disease): people with certain medical conditions.
3. Centers for Disease Control and Prevention, 2020, Interim guidance for antigen testing (Serology) for SARS-CoV-2.
4. Control and Prevention, 2020, Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19).
5. Libster R., Perez Marc G. and Wappner D., Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med.
6. Kenneth M., 2020, Corona virus disease 2019 (COVID -19) uptodate , last updated 25th March.
7. Yang X., Yu Y., Xu J., Shu H., Xia J. and Liu H., 2020, Clinical course and outcomes of critically ill patients with SARS CoV-2 Pneumonia in Wuhan, China: a single centred, retrospective, observational study Lancet Respir Med.
8. Wang D., Hu B. and Hu C., 2020, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.
9. Xie X., Zhong Z. and Zhao W., 2020, Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology; 200343.
10. Sudre CH., Murray B. and Varsavsky T., Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the COVID symptoms study app. Nat Med.
11. REMAP-CAP PR, 2021, International Trial of SARS-CoV-2 Convalescent Plasma Pauses Enrollment of Critically Ill COVID-19 Patients.
12. Neunert C., Terrell DR. and Arnold DM., 2019, American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv.;3(23):38293866. - PMC – PubMed.
13. Polack F.P., Thomas S.J. and Kitchin N., 2020, Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med.;383:2603‐2615. - PMC – PubMed.
14. Walsh EE., Frenck RW Jr. and Falsey AR., 2020, Safety and immunogenicity of two RNA‐based Covid‐19 vaccine candidates. N Engl J Med.
15. Jackson LA., Anderson EJ. and Rouphael NG., 2020. An mRNA vaccine against SARS‐CoV‐2 ‐ preliminary report. N Engl J Med.;383(20):1920‐1931. - PMC PubMed.
16. Grady D. and Mazzei P., 2021, Doctor's death after Covid vaccine is being investigated. The New York Times.
17. World Health Organization. Coronavirus disease (COVID-19) technical guidance:Surveillance and case definitions, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions, (Accessed on February 28, 2020).
18. Guo L., Ren L., Yang S., Xiao M., Chang Yang F., Dela Cruz C.S. and Wang Y., 2020, Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis.; 3786.
19. Wang W., Xu Y., Gao R., Lu R., Han K., Wu G. and Tan W., 2020, Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA.
20. Ai T., Yang Z. and Hou H., 2020, Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology; 200642.
21. Peng Q.Y., Wang X.T. and Zhang L.N., 2020, Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic. Intensive Care Med. Mar 12: 1- 2.
22. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W. and Lu R., 2020, A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine.
2. Centers for Disease Control and Prevention. COVID-19 (coronavirus disease): people with certain medical conditions.
3. Centers for Disease Control and Prevention, 2020, Interim guidance for antigen testing (Serology) for SARS-CoV-2.
4. Control and Prevention, 2020, Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19).
5. Libster R., Perez Marc G. and Wappner D., Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med.
6. Kenneth M., 2020, Corona virus disease 2019 (COVID -19) uptodate , last updated 25th March.
7. Yang X., Yu Y., Xu J., Shu H., Xia J. and Liu H., 2020, Clinical course and outcomes of critically ill patients with SARS CoV-2 Pneumonia in Wuhan, China: a single centred, retrospective, observational study Lancet Respir Med.
8. Wang D., Hu B. and Hu C., 2020, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.
9. Xie X., Zhong Z. and Zhao W., 2020, Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology; 200343.
10. Sudre CH., Murray B. and Varsavsky T., Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the COVID symptoms study app. Nat Med.
11. REMAP-CAP PR, 2021, International Trial of SARS-CoV-2 Convalescent Plasma Pauses Enrollment of Critically Ill COVID-19 Patients.
12. Neunert C., Terrell DR. and Arnold DM., 2019, American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv.;3(23):38293866. - PMC – PubMed.
13. Polack F.P., Thomas S.J. and Kitchin N., 2020, Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med.;383:2603‐2615. - PMC – PubMed.
14. Walsh EE., Frenck RW Jr. and Falsey AR., 2020, Safety and immunogenicity of two RNA‐based Covid‐19 vaccine candidates. N Engl J Med.
15. Jackson LA., Anderson EJ. and Rouphael NG., 2020. An mRNA vaccine against SARS‐CoV‐2 ‐ preliminary report. N Engl J Med.;383(20):1920‐1931. - PMC PubMed.
16. Grady D. and Mazzei P., 2021, Doctor's death after Covid vaccine is being investigated. The New York Times.
17. World Health Organization. Coronavirus disease (COVID-19) technical guidance:Surveillance and case definitions, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions, (Accessed on February 28, 2020).
18. Guo L., Ren L., Yang S., Xiao M., Chang Yang F., Dela Cruz C.S. and Wang Y., 2020, Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis.; 3786.
19. Wang W., Xu Y., Gao R., Lu R., Han K., Wu G. and Tan W., 2020, Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA.
20. Ai T., Yang Z. and Hou H., 2020, Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology; 200642.
21. Peng Q.Y., Wang X.T. and Zhang L.N., 2020, Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic. Intensive Care Med. Mar 12: 1- 2.
22. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W. and Lu R., 2020, A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine.
Article Sidebar
Published
Apr 5, 2023
Article Details
How to Cite
Omer Qasim Ahmed, Ahmed Abdulghani Mustafa, Akram Raad Salim, & Mustafa Amer Abdullah. (2023). Effects of some biological factors on Coronavirus. Journal of Population Therapeutics and Clinical Pharmacology, 30(5), 585-597. https://doi.org/10.47750/jptcp.2023.30.05.058
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Omer Qasim Ahmed, Ahmed Abdulghani Mustafa, Akram Raad Salim, & Mustafa Amer Abdullah. (2023). Effects of some biological factors on Coronavirus. Journal of Population Therapeutics and Clinical Pharmacology, 30(5), 585-597. https://doi.org/10.47750/jptcp.2023.30.05.058